Literature DB >> 17393169

[Differential diagnosis of ovarian metastases].

S Hauptmann1.   

Abstract

Ovarian metastases comprise 7-10% of all malignant ovarian tumors. The detection of ovarian metastases is difficult because primary ovarian tumors are a morphologically very heterogeneous group, and metastases can simulate an primary ovarian tumor perfectly. A correct diagnosis, however, is most important in order to avoid an unnecessary and ineffective chemotherapy. Therefore, every morphologically unusual ovarian tumor should raise doubts. In addition, mucinous and endometrioid tumors may also be metastatic in nature. Immunohistochemistry, as well as knowledge on the patient's history, will clarify most of the suspicious cases.

Entities:  

Mesh:

Year:  2007        PMID: 17393169     DOI: 10.1007/s00292-007-0906-x

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  29 in total

1.  beta-Catenin expression pattern, beta-catenin gene mutations, and microsatellite instability in endometrioid ovarian carcinomas and synchronous endometrial carcinomas.

Authors:  G Moreno-Bueno; C Gamallo; L Pérez-Gallego; J C de Mora; A Suárez; J Palacios
Journal:  Diagn Mol Pathol       Date:  2001-06

Review 2.  Ovarian carcinomas, including secondary tumors: diagnostically challenging areas.

Authors:  Jaime Prat
Journal:  Mod Pathol       Date:  2005-02       Impact factor: 7.842

3.  Necrosis in 84 ovarian carcinomas: a morphologic study of primary versus metastatic colonic carcinoma with a selective immunohistochemical analysis of cytokeratin subtypes and carcinoembryonic antigen.

Authors:  D C DeCostanzo; J M Elias; J C Chumas
Journal:  Int J Gynecol Pathol       Date:  1997-07       Impact factor: 2.762

4.  Review of the granulosa-theca cell tumors from the emil Novak ovarian tumor registry.

Authors:  H S Cronjé; I Niemand; R H Bam; J D Woodruff
Journal:  Am J Obstet Gynecol       Date:  1999-02       Impact factor: 8.661

5.  Keratins 7 and 20 as diagnostic markers of carcinomas metastatic to the ovary.

Authors:  C C Wauters; F Smedts; L G Gerrits; F T Bosman; F C Ramaekers
Journal:  Hum Pathol       Date:  1995-08       Impact factor: 3.466

6.  Use of novel immunohistochemical markers expressed in colonic adenocarcinoma to distinguish primary ovarian tumors from metastatic colorectal carcinoma.

Authors:  Sanjay Logani; Esther Oliva; Paula M Arnell; Mahul B Amin; Robert H Young
Journal:  Mod Pathol       Date:  2005-01       Impact factor: 7.842

7.  Genetics of synchronous uterine and ovarian endometrioid carcinoma: combined analyses of loss of heterozygosity, PTEN mutation, and microsatellite instability.

Authors:  Hiroaki Fujii; Toshiharu Matsumoto; Manabu Yoshida; Yoshiaki Furugen; Tetsuya Takagaki; Keiichi Iwabuchi; Yasuo Nakata; Yoshitake Takagi; Takuya Moriya; Naomi Ohtsuji; Mareki Ohtsuji; Sachiko Hirose; Toshikazu Shirai
Journal:  Hum Pathol       Date:  2002-04       Impact factor: 3.466

8.  Metastases from carcinomas of the pancreas simulating primary mucinous tumors of the ovary. A report of seven cases.

Authors:  R H Young; W R Hart
Journal:  Am J Surg Pathol       Date:  1989-09       Impact factor: 6.394

9.  Metastatic intestinal carcinomas simulating primary ovarian clear cell carcinoma and secretory endometrioid carcinoma: a clinicopathologic and immunohistochemical study of five cases.

Authors:  R H Young; W R Hart
Journal:  Am J Surg Pathol       Date:  1998-07       Impact factor: 6.394

10.  Potential utility of uroplakin III, thrombomodulin, high molecular weight cytokeratin, and cytokeratin 20 in noninvasive, invasive, and metastatic urothelial (transitional cell) carcinomas.

Authors:  Douglas C Parker; Andrew L Folpe; Julie Bell; Esther Oliva; Robert H Young; Cynthia Cohen; Mahul B Amin
Journal:  Am J Surg Pathol       Date:  2003-01       Impact factor: 6.394

View more
  1 in total

1.  Ovarian metastases from ALK-positive lung adenocarcinoma: a case report and review of the literature.

Authors:  Huixin Li; Yan Chen; Yingchun Wang; Lin Zhou; Zhongfu Tian; Mengyu Liu; Yang Li; Hanzi Xu; Wangfei Wu; Zhen Gong
Journal:  Transl Cancer Res       Date:  2022-09       Impact factor: 0.496

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.